InterVenn Biosciences

Immune checkpoint inhibitors are powerful therapeutics in the fight against cancer, but not all patients respond to treatment. Being able to predict patient outcomes is more important than ever - and glycoproteins show immense promise as both prognostic and predictive biomarkers. Read the article on BioPharma Dive: https://ow.ly/aylG50SHrNp #Immunotherapy #Pharma #Glycoproteomics #CancerResearch

📢 Calling all academic researchers! Apply to our inaugural Glycoproteomic Innovator Grant: Now open for applications through August 16, 2024. This grant provides a unique opportunity for researchers to leverage our GlycoVision™ Platform to analyze up to 200 human serum or plasma samples; discover new, high-performing biomarkers that can advance the state of disease diagnosis, progression, and treatment decisions. For more details and to apply, please visit: https://lnkd.in/g7g8ujtt #Research #Grant #Glycoproteomics

Want a crash course in the world of glycoproteomics? We've got you covered. In this video, you'll learn the role of glycoproteomics in disease research, drug development and personalized medicine and understand why we're so passionate about studying this untapped layer of biology. The future of precision medicine is #glyco. https://lnkd.in/gBMqkp-R

Please join us in listening to our bioinformatics expert, Matthew Campbell, PhD, speak at Neo4j’s LifeScience hybrid event on June 12 at 9:00 EDT | 13:00 BST | 14:00 CEST | 18:30 IST!    Knowledge graphs can uncover hidden relationships and patterns across massive datasets. At InterVenn, we use this technology to develop a deeper understanding of glycobiology and reveal novel insights into disease-related pathways.    Register here to listen in to the conversation: https://lnkd.in/dq9WxdAU #knowledgegraph #glycoproteomics #bioinformatics

Are you attending #BIO June 3-6 in San Diego? If you have an interest in learning more about InterVenn's glycoproteomic biomarker discovery services, don't hesitate to reach out to Kim MacMartin-Moglia, VP of BD to schedule a meeting. #BIO2024 #Glycoproteomics #Biotech

Our team will be presenting at the ASMS Annual Conference in Anaheim! 🔬 We'll be showcasing our latest research that advances our understanding of glycoproteomics through mass spectrometry. Presentation: Mass Spectrometric Analysis of Glycopeptides Enriched by Anion Exchange-Mediated Methods Reveals PolyLacNAc-Extended N-Glycans in Melanoma Cells. Maryam Baniasad, Ph.D. Monday, June 3, 10:10 AM - 10:30 AM PT, Room 207ABC, Level 2 Posters: 388 - Label-free quantification of serum glycopeptides reveals novel biomarkers for advanced colorectal adenoma. Gege Xu, Ph.D. 389 - Reproducible enrichment of N-glycopeptides with HPLC Fractionation. Rachel Rice See you there! #ASMS2024 #MassSpectrometry #Glycoproteomics

Will you be at #ASCO May 31 - June 4 in Chicago? Schedule a meeting with Miles McKenna, Director of BD, to learn more about our glycoproteomic biomarker discovery services. See you there!

Diagnostic tests for screening, triaging, and staging epithelial ovarian cancer (EOC) are currently lacking. However, blood glycoproteomic profiling shows significant promise in meeting this need. In our latest study we demonstrate that blood-based glycopeptide biomarkers have the potential to distinguish benign from malignant pelvic masses, and early- from late-stage epithelial ovarian cancer (EOC). Access the full paper in the British Journal of Cancer: https://ow.ly/QowK50RYP8g #OvarianCancer #EarlyDetection #glycoproteomics

Check out this excellent overview of disease glycosylation patterns recently published by the team at the Center for Proteomics and Metabolomics at Leiden University Medical Center. Further discussion in the review suggests that total blood N-glycome (TBNG) studies should be paired with glycoproteomic analyses at the glycopeptide level in order to identify the glycoproteins and glycosylation sites that contribute to TBNG signatures. InterVenn’s research has shown that these kinds of glycoproteomic studies have significant potential in revealing clinical disease #biomarkers. To learn more on this topic: https://lnkd.in/gMBNY2TM InterVenn’s clinical biomarker publications: https://lnkd.in/gsnQeZVe #Biotech #Pharma #Glycobiology #BiomarkerDiscovery

Recent press coverage by News Medical (https://lnkd.in/gbzFnFP3) regarding our paper published this week in the British Journal of Cancer highlights how we explore the potential utility of serum glycoproteomic profiling to distinguish benign from malignant pelvic masses, and early from late-stage epithelial ovarian cancer. 📗 Read our paper: https://lnkd.in/gdYAPxWh #OvarianCancer #Glycoproteomics #Pharma #Biotech